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Inhibitory constants ($) between 5 and 35 nM were derived (under different conditions of pH and ionic strength) for 
the interaction of HIV-1 proteinase with acetyl-pepstatin and H-261, two characteristic nhibitors of aspartic proteinases. 
Thus this enzyme, essential for replication of the AIDS virus, may be classified unequivocally as belonging to this protein- 
ase family. 
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1. INTRODUCTION 
The proteinase encoded within the viral genome 
of HIV is required for processing of the viral gag 
proteins together with generation of other en- 
zymatic activities (e.g. reverse transcriptase) essen- 
tial for viral replication [l]. It has been postulated 
that this enzyme belongs to the aspartic proteinase 
family on the basis of (i) the presence of an Asp- 
Thr-Gly sequence in the predicted structure of the 
enzyme [2], (ii) mutation of this Asp to Ala [3] or 
Thr [4] with concomitant loss of processing activi- 
ty and (iii) computer graphics modelling calcula- 
tions which predict that the viral proteinase has a 
folding pattern for the central core of the molecule 
virtually identical to that for archetypal aspartic 
proteinases [5]. 
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Abbreviation: #[CHOH-CHz], the hydroxy ethyl peptide bond 
replacement; see (1985) J. Biol. Chem. 260, 14-42 
Aspartic proteinases include among their 
number such enzymes as pepsin, renin, cathepsin 
D and cathepsin E and, characteristically, the en- 
zymes of this family are inhibited effectively by 
certain compounds of natural or synthetic origin 
e.g. pepstatin. This contains two residues of the 
unusual amino acid statine (4-amino-3-hydroxy- 
6-methylheptanoic acid), which acts as a transition 
state dipeptide analogue of the two residues con- 
tributing the scissile peptide bond in a substrate. 
However, in a number of previous reports (e.g. 
[4,6,7]), pepstatin has been demonstrated to be a 
rather poor inhibitor of HIV-l proteinase. The 
simplest interpretation of this finding therefore is 
that the AIDS virus proteinase is not an aspartic 
proteinase. Pepstatin is most commonly described 
as the isovaleryl-derivative, viz. isovaleryl-Val-Val- 
Sta-Ala-Sta and is commercially available as such. 
However, other forms of the molecule e.g. acetyl- 
pepstatin = Ac-Val-Val-Sta-Ala-Sta and lactoyl- 
pepstatin = Lac-Val-Sta-Ala-Sta have also been 
reported [8,9] and characterised as inhibitors of 
classical aspartic proteinases [lo]. The effect of 
these compounds on the viral proteinase was 
therefore examined in detail. 
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2. MATERIALS AND METHODS 28 7 
24 
Acetyl-pepstatin (S-PI) and lactoyl-pepstatin were generous 
gifts from Professor S. Murao and Dr K. Oda, Osaka Prefec- 
ture University, Japan and Dr T. Aoyagi, Institute of Microbial 
Chemistry, Tokyo, Japan, respectively. The synthetic renin in- 
hibitor, H-261, was kindly provided by Professor M. Szelke, 
Ferring Research Institute, Southampton, England. 
HIV-l proteinase was expressed in E. coli in two different 
constructs and was extracted and purified to an extent such that 
the enzyme represented about 15-30% of the total protein in 
the preparations used (full accounts of the details have been [l l] 
or will be described elsewhere). Closely similar results were ob- 
tained with the two enzyme preparations. No activity what- 
soever was observed in control cell extracts prepared in an 
identical manner but using vector without proteinase insert. The 
peptide substrate Tyr-Val-Ser-Gln-Asn-Phe*Pro-Ile-Val-Gln- 
Asn-Arg was synthesised by solid phase methods employing 
symmetric anhydride chemistry in an ABI model 430A syn- 
thesiser in the Protein Chemistry Core Facility of the University 
of Florida as described previously [12]. 
Incubation of this peptide with recombinant HIV-l pro- 
teinase resulted in specific cleavage at the Phe-Pro bond. Initial 
rates of hydrolysis were determined by removal of samples at 3 
different time points followed by analysis by reversed-phase 
HPLC/FPLC with quantitation of the cleavage product, Tyr- 
Val-Ser-Gln-Asn-Phe, generated by the proteinase action. 
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3. RESULTS AND DISCUSSION 
Initial rates of cleavage of the synthetic pep- 
tide Tyr-Val-Ser-Gln-Asn-Phe*Pro-Ile-Val-Gln- 
Asn-Arg specifically at the Phe*Pro bond were 
measured at a variety of pH values (but at constant 
ionic strength, fig. 1). Since substrate hydrolysis 
and inhibitor interaction with conventional aspar- 
tic proteinases is most effective at pH values below 
approx. 5.5 [ 12,131, more detailed investigations 
were carried out initially, therefore, in the region 
of pH 5 but at a higher ionic strength since 
preliminary investigations (not shown) had in- 
dicated that the enzyme was more active under 
such conditions. In a buffered solution consisting 
of 20 mM acetic acid/20 mM MesMO mM Tris 
and 800 mM NaCl, pH 5.0 01 = 0.82 M), 
Michaelis-Menten kinetics were observed for the 
substrate hydrolysis and a mean Km value of 140 f 
35 /rM was obtained. With the ready availability of 
such a good substrate, it was then possible to ex- 
amine the interaction of the HIV-l proteinase with 
a number of classical inhibitors of aspartic pro- 
teinases. As discussed previously, isovaleryl- 
pepstatin was confirmed to be a rather poor in- 
Fig.1. pH dependence of the hydrolysis of Tyr-Val-Ser-Gln- 
Asn-Phe*Pro-Ile-Val-Gln-Asn-Arg by HIV-l proteinase. 
Substrate at a fixed concentration of 125 CM was incubated at 
30°C with HIV-l proteinase (approx. 0.1 /cg) in buffers 
composed of 20 mM acetic acid, 20 mM Mes and 40 mM Tris 
at each of the indicated pH values but with a total ionic strength 
always at ,u = 0.1 M [18]. At three appropriate times (normally 
all less than 10 min), aliquots were removed and the hydrolysis 
was quenched by the addition of 5% (v/v) trifluoroacetic acid 
before injection of the samples into a reversed-phase HPLC 
(Novapak, Waters) or a PepRP-FPLC (Pharmacia Ltd.) 
column. Elution was performed with a linear gradient of 
acetonitrile over IS-25 min. Peaks of (substrate and) generated 
products were quantitated by integration of the absorbances at 
254 or 215 nm. Rates of reaction were calculated from 
computer&d fits of each set of linear time course values thus 
derived. The solid line is a computer-generated fit of the points 
to a system with two acid dissociation groups (pKai = 3.1 and 
pKa2 = 6.7), assuming that enzymic activity is expressed only in 
hibitor and lactoyl-pepstatin was even worse since 
concentrations in the micromolar range (0.4pM 
and 6 PM respectively) were required for 50% in- 
hibition. Indeed, it has very recently been reported 
that a number of synthetic statine-containing in- 
hibitors were not effective unless concentrations 
verging on millimolar were used [14]. However, 
the acetyl-derivative of pepstatin was much more 
effective (table 1) with a mean Ki value of 35 nM 
measured for the competitive inhibition in this buf- 
fer at pH 5.0. 
Consequently these investigations were expand- 
ed to include the synthetic compound H-261 = 
tBoc-His-Pro-Phe-His-Leu #[CHOH-CHz]Val-Ile- 
His which contains the transition state analogue - 
CHOH-CH2 instead of the CO-NH of the scissile 
114 
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Table 1 
The effect of HIV-l proteinase of a naturally occurring and a 
synthetic inhibitor of aspartic proteinases 
pH value) 
PH Ki (nM) 
Acetyl-pepstatin H-261 
4.7 20 5 
5.0 35 15 
7.0 >lOOO 29 
Reactions were carried out at 30°C in buffers consisting of 
20 mM acetic acid, 20 mM Mes, 40 mM Tris, pH 5.0 (/r = 
0.82 M); 0.1 M sodium acetate buffer, pH 4.7, containing 
4 mM EDTA, 5 mM mercaptoethanol and 1000 mM NaCl & = 
1.06 M); and 0.1 M Mes buffer, pH 7.0, containing 4 mM 
EDTA, 5 mM mercaptoethanol and 1000 mM NaCl but 
otherwise as described in the legends to figs 1 and 2. The 
estimated precision of the values obtained is in the range of 
f 20% except at pH 7.0 where the value given (“) for H-261 is 
an ICse determined at a substrate concentration of 84/M 
(because of the linear dependence of v with varying [S] at this 
peptide bond in a substrate. This has been shown 
to be a very potent inhibitor not only of human 
renin [ 15,161 but also of most other typical aspartic 
proteinases examined [171. It was also found to be 
a competitive inhibitor of the HIV-proteinase with 
a mean Ki value of 15 nM in the pH 5.0 buffer 
(table 1). A further rationale behind the examina- 
tion of these compounds was in an attempt o find 
an active site titrant to permit accurate quantita- 
tion of the amount of active HIV-l proteinase in 
any solution. Currently, such measurements to 
define this essential parameter cannot be made ex- 
perimentally, due to the absence of just such a 
titrant . 
Consequently, buffer conditions under which 
the assays were performed were varied in order to 
try to improve yet further the proteinase-inhibitor 
interactions. It was found that by using a sodium 
acetate buffer at pH 4.7 containing 1 M NaCl 01 = 
1.06 M), while Michaelis-Menten kinetics were still 
observed for the interaction of the synthetic pep- 
tide substrate, a (better) Km value of 60 & 8 PM 
was measured. On this basis, the interactions of 
acetyl-pepstatin and H-261 were re-determined 
under these buffer conditions at pH 4.7 (table 1). 
Competitive inhibition was observed in both cases 
and, while the acetyl-pepstatin interaction (a 
representative plot is shown in fig.2) was still too 
14r . 
1.2 - 
k 
-K;* / - 
c 3 kn,x , 4 
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Fig.2. Inhibition of HIV-l proteinase by acetyl-pepstatin. 
HIV-l proteinase was incubated with various concentrations of 
in the total absence of inhibitor. 
acetyl-pepstatin at a fiied concentration (63 PM) of substrate 
peptide in 100 mM sodium acetate buffer, pH 4.7, containing 
1 M NaCl, 4 mM EDTA, 5 mM mercaptoethanol at 30°C. 
Initial rates were determined from analysis of time courses of 
the reactions as described in the legend to fig. 1. The horizontal 
line is included at the value of l/V,, determined by varying [S] 
weak (mean Ki = 20 nM) for this compound to be 
of value as a titrant, the Ki for H-261 is ap- 
proaching the level necessary (c 1 nM) for 
stoichiometric binding. Since this compound was 
originally designed by Szelke and co-workers 
[ 15,161 to mimic the site in angiotensinogen 
cleaved by renin yet still displays effective inhibi- 
tion of the viral enzyme (which has a totally dif- 
ferent specificity), it would appear that a synthetic 
compound containing a peptide bond replacement 
and centred around an HIV cleavage site would be 
likely to provide an active site titrant. 
At pH 7.0, the synthetic peptide substrate in- 
teracted much less favourably with the proteinase. 
Plots of v versus [substrate] were essentially linear 
up to concentrations that were limited by the sup- 
ply of available material. Km was estimated to ex- 
ceed 17OO/cM in 100 mM Mes buffer, pH 7.0, 
containing 1 M NaCl. Nevertheless, hydrolysis of 
the substrate was very readily measured at pH 7.0, 
even if saturation could not be achieved. The ap- 
parent reduction in activity observed at the higher 
pH values (fig. 1) would thus appear to result from 
a diminished ability of the synthetic substrate to in: 
teract with the proteinase. Whether such an effect 
on binding would be observed with a polyprotein 
substrate (e.g. gag precursor) is clearly worthy of 
further investigation. 
115 
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In contrast to its effect at the lower pH values, 
acetyl-pepstatin at a concentration as high as 1 pM 
was only able to inhibit the proteinase by approx. 
35% at pH 7.0 (table 1). Such a diminution in the 
inhibitory potency of pepstatins at pH values 
above approx. 5.5 has been observed previously 
with typical aspartic proteinases (e.g. [13]) and in- 
deed has been used to effect in developing affinity 
chromatographic procedures for the convenient 
purification of the enzymes [19]. H-261, however, 
remained an adequate inhibitor (table 1) with an 
ICSO value of 25 nM estimated at pH 7.0. Since no 
detailed structural information is yet available for 
retroviral proteinases, this different behaviour of 
the two inhibitors cannot be readily rationalised at 
present. H-261 is an excellent inhibitor of all aspar- 
tic proteinases due to the ability of the hydroxyl 
group of the peptide bond surrogate to interact 
with both active site aspartic acid residues [15]. 
Since acetyl-pepstatin also contains such a hydrox- 
yl group, the different response in binding of these 
two compounds with changing pH implies that 
H-261 binding may involve some additional active 
site interactions, perhaps derived from the 
hydrophilic histidine residues, for example. Alter- 
natively, the loss of binding observed for acetyl- 
pepstatin could be due to repulsion of its C- 
terminal carboxyl group by some group (e.g. a 
COOH) in the enzyme’s active site that becomes 
negatively charged as the pH is raised from 5 to 7. 
This repulsion may not be manifested for H-261 
due to the terminal His residue which could permit 
an altered binding conformation. Nevertheless, it 
seems that the proteinase which is so vital for the 
reproduction of the AIDS virus can now be 
classified with certainty as belonging to the aspar- 
tic proteinase family. The investigations described 
herein provide only a preliminary insight into 
structure-function relationships of this proteinase 
but do demonstrate that it is feasible to inhibit the 
HIV (aspartic) proteinase effectively in the pH 
range that is likely to exist within virally-infected 
cells. With the central role of this enzyme in 
retrovirus maturation, it would appear that these 
observations provide a substantial basis from 
which to launch further studies for the rational 
design of selective inhibitors 
sensitive viral target enzyme. 
of this strategically 
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NOTE ADDED IN PROOF 
Following submission of this manuscript, reports appeared subsequently describing the crystal structures 
of two retroviral proteinases at medium-high resolution (from Rous sarcoma virus [20] and HIV-l itself [21] 
and demonstrating their structural homology with aspartic proteinases. In a third report on molecular 
modelling of possible substrate interactions in the HIV-l proteinase active site [22], it was predicted ‘that 
a smaller residue’ (such as an acetyl moiety) ‘would bind in subsite P4, in agreement with the findings 
reported herein. 
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